Eterobarb

Eterobarb

SCHEMBL35417

CCC1(c2ccccc2)C(=O)N(COC)C(=O)N(COC)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 1.00
CYP2C19 P33261 4/20 0.50
KMT2A Q03164 3/20 0.44
TSHR P16473 2/20 0.44
MEN1 O00255 2/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
ELANE P08246 1/20 0.38
BACE1 P56817 1/20 0.37
BACE2 Q9Y5Z0 1/20 0.37
MITF O75030 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11734991 0.85 LMNA (0.74) LMNACYP2C19KMT2ATSHRMEN1
T-2000 SCHEMBL711204 0.82 LMNA (0.69) LMNACYP2C19KMT2ATSHRMEN1
SCHEMBL11740356 0.81 LMNA (0.68) LMNACYP2C19KMT2ATSHRMEN1
SCHEMBL11864115 0.81 LMNA (0.68) LMNACYP2C19KMT2ATSHRMEN1
SCHEMBL11857604 0.81 LMNA (0.68) LMNACYP2C19KMT2ATSHRMEN1
SCHEMBL11426802 0.78 LMNA (0.64) LMNACYP2C19KMT2ATSHRMEN1
SCHEMBL14035379 0.78 LMNA (0.63) LMNACYP2C19TSHRNPSR1BACE1
SCHEMBL17794053 0.75 LMNA (0.68) LMNACYP2C19KMT2ATSHRMEN1
SCHEMBL1714649 0.74 LMNA (0.58) LMNACYP2C19KMT2ATSHRMEN1
SCHEMBL11706896 0.74 LMNA (0.58) LMNACYP2C19KMT2ATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101484152-A Therapeutic combination for painful medical conditions SANOL ARZNEI SCHWARZ GMBH (DE) 2009-07-15 CN claimed
EP-2026788-A1 THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS SCHWARZ PHARMA AG (DE) 2009-02-25 EP claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007141018-A1 THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS SCHWARZ PHARMA AG (DE) 2007-12-13 WO claimed
WO-2007105229-A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND PROCESS THEREOF PANACEA BIOTEC LTD. (IN) 2007-09-20 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5955103-A Dosage form comprising antiepileptic drug ALZA CORPORATION (US) 1999-09-21 US claimed
US-5906832-A Method for treating epilepsies ALZA CORPORATION (US) 1999-05-25 US claimed
US-5876750-A Effective therapy for epilepsies ALZA CORPORATION (US) 1999-03-02 US claimed
US-5863558-A Effective therapy for epilepsies ALZA CORPORATION (US) 1999-01-26 US claimed
EP-0758228-A1 EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS ALZA CORPORATION (US) 1997-02-19 EP claimed
WO-1995029665-A1 EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS ALZA CORPORATION (US) 1995-11-09 WO claimed
US-4029662-A Method of making barbituric acid derivatives BRISTOL-MYERS COMPANY (US) 1977-06-14 US claimed